An expected surge in generic GLP-1s is anticipated to reshape not only pharmaceutical pricing and access but also the global MedTech ecosystem supporting drug delivery.

Akila Samiiya, Lead Analyst at Beroe and Rahul R Patil, Medzus, break down what the rise of generics means for drug delivery device procurement and what leaders should be doing about it now.

Read the full Pharmaceutical Exec article herearrow-right

Related Reading

Featured Image

02 Nov, 2026

Turning procurement intelligence into defensible action

Featured Image

28 Oct, 2026

Rethinking procurement: Why supply chains must move from episodic strategy to continuous optimization

Featured Image

19 Oct, 2026

Real-time clinical trials: what it means for procurement strategy